SKB BIO-B (06990) announced that its self-developed ITGB6-targeting antibody-drug conjugate (ADC) SKB105 (also known as CR-003) has received approval for its Investigational New Drug (IND) application from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA). The approval is for the treatment of advanced solid tumors.

In December 2025, the company entered into a strategic collaboration with Crescent Biopharma, Inc. concerning SKB105/CR-003 and SKB118, a PD-1xVEGF bispecific antibody (also known as CR-001). Under the agreement, SKB BIO-B granted Crescent exclusive rights to research, develop, produce, and commercialize SKB105/CR-003 in markets outside the United States, Europe, and all other Greater China regions (including Mainland China, Hong Kong, Macau, and Taiwan). In return, Crescent granted SKB BIO-B exclusive rights to research, develop, produce, and commercialize SKB118/CR-001 within the Greater China region.

The company plans to submit an IND application for SKB118/CR-001 to the CDE of the NMPA in the near future.